Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients-Reference-Cited by-同舟云学术

Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients

Published:2021-11-29 Issue:2 Volume:111 Page:485-495
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Prohn Marita¹,Cho Carolyn R.²,Viberg Anders¹,Dykstra Kevin¹,Davis Casey²,Sabato Philip²,Stone Julie²,Badshah Cyrus²,Murata Yoshihiko²,Leavitt Randi²,Fancourt Craig²,Macha Sreeraj²

Affiliation:

1. qPharmetra LLC Nijmegen The Netherlands

2. Merck & Co., Inc. Kenilworth New Jersey USA

Funder

Merck Sharp and Dohme

Merck

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2456

Reference28 articles.

1. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis

2. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

3. Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future

4. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy

5. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo‐HSCT): A systematic review, meta‐analysis, and meta‐regression analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetics and Pharmacodynamics of Letermovir in Allogenic Hematopoietic Cell Transplantation;Clinical Pharmacokinetics;2024-07

2. Antiviral Agents: Letermovir;Global Virology IV: Viral Disease Diagnosis and Treatment Delivery in the 21st Century;2024

3. Pharmacokinetics, Safety, and Tolerability of Letermovir Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Subjects;Clinical Pharmacology in Drug Development;2022-03-02